ConvaTec Group PLC
CTEC
Company Profile
Business description
Originally spun out of Bristol-Myers Squibb, ConvaTec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
Contact
20 Eastbourne Terrace
7th Floor
Paddington
LondonW2 6LG
GBRT: +44 7826447807
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
10,489
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,890.80 | 74.40 | 0.84% |
| CAC 40 | 7,822.00 | 99.91 | 1.29% |
| DAX 40 | 24,370.93 | 361.55 | 1.51% |
| Dow JONES (US) | 44,393.38 | 138.60 | 0.31% |
| FTSE 100 | 8,972.64 | 46.09 | 0.52% |
| HKSE | 24,498.95 | 18.81 | -0.08% |
| NASDAQ | 20,891.01 | 160.52 | 0.77% |
| Nikkei 225 | 39,901.19 | 237.79 | 0.60% |
| NZX 50 Index | 12,905.41 | 150.82 | 1.18% |
| S&P 500 | 6,289.02 | 25.32 | 0.40% |
| S&P/ASX 200 | 8,639.00 | 77.20 | 0.90% |
| SSE Composite Index | 3,516.83 | 13.05 | 0.37% |